| The partnership, between the University and global pharmaceutical company GlaxoSmithKline (GSK), will build upon the work of researchers who have identified a molecular mechanism that plays a major role in the life-threatening liver disease that develops in a population of patients with a particular mutant gene. |
 |
| 07th September, 2012 |
Skip to content
Supporting alphas, their friends and families since 1997